German healthcare firm Merck KGaA is boosting investments in China, aiming for strategic collaborations with local companies.
Zacks Investment Research on MSN
Will weak Gardasil sales continue to weigh on MRK's top line in 2026?
Merck MRK continues to face challenges with its second-largest product, Gardasil, which is a vaccine approved to prevent certain cancers caused by the human papillomavirus. While the vaccine’s sales ...
Merck (NSE:PROR) & Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in ...
Oct 30 (Reuters) - Merck & Co (MRK.N), opens new tab posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus ...
Abbisko Therapeutics Co. Ltd. and its partner Merck KGaA got an early Christmas present from China’s National Medical Products Administration (NMPA) with the approval of pimicotinib (ABSK-021), the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results